Key takeaways: GLP-1 receptor agonists (e.g., semaglutide, liraglutide, tirzapeptide) are now approved for weight loss for overweight teens and adults
In addition to the improvement in HbA1c and glucose profile, tirzepatide has also demonstrated to improve insulin resistance, as assessed by HOMA-IR
It explored the mechanisms of action of GLP-1RAs and their therapeutic potential in a wide array of diseases, such as diabetes mellitus, providing new insights into metabolic disease management
Specifically, Mller cells are important in the pathogenesis of glaucoma by providing support across the retinal span
However, it may have different instructions and side effects than those covered here
People with diabetes, particularly severe diabetes, tend to lose less weight with GLP-1s than people without diabetes, so microdosing is less likely to be as effective, though their dose should only be increased as they tolerate it. George said that in her professional opinion, microdosing is a potential option for patients with smaller amounts of weight to lose or as a bridge to start, or wean off, regular GLP-1 medications